The Advisory Committee on Immunization Practices (ACIP) recently approved the Recommended Immunization Schedule for Adults Aged 19 Years and Older that summarizes recommendations on the use of vaccines routinely recommended for adults aged ≥19 years.
Key changes from the 2015 adult immunization schedule include:
- Interval change for 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) from “6 to 12 months” to “at least 1 year” for adults aged ≥65 years who do not have immunocompromising conditions, anatomical or functional asplenia, cerebrospinal fluid leaks, or cochlear implants. The interval for adults aged ≥19 years with any of these conditions is at least 8 weeks.
- Serogroup B meningococcal (MenB) vaccine series should be administered to certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease.
- Men B vaccine series may be administered to adolescents and young adults aged 16 through 23 years (preferred age is 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease.
- Nine-valent human papillomavirus (HPV) vaccine (9vHPV) has been added to the schedule and can be used for routine vaccination of females and males against HPV.
Adults are recommended specific vaccinations depending on their age, underlying medical conditions, lifestyle, prior vaccinations, and other factors. Vaccination coverage among U.S. adults, however, remains low despite longstanding vaccine recommendations.
Researchers conducted a study to survey the vaccination coverage among adult populations in the U.S. using data from the National Health Interview Survey (NHIS). Reports were obtained between August 2013–June 2014 for influenza vaccination, and between January–December 2014 for pneumococcal, tetanus, and diphtheria (Td) and tetanus and diphtheria with acellular pertussis (Tdap), hepatitis A, hepatitis B, herpes zoster, and human papillomavirus (HPV) vaccination.